Ficolin-2 amplifies inflammation in macrophage-smooth muscle cell cross-talk and increases monocyte transmigration by mechanisms involving IL-1β and IL-6.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
08 11 2023
Historique:
received: 06 07 2023
accepted: 04 11 2023
medline: 10 11 2023
pubmed: 9 11 2023
entrez: 8 11 2023
Statut: epublish

Résumé

Ficolin-2, recently identified in atherosclerotic plaques, has been correlated with future acute cardiovascular events, but its role remains unknown. We hypothesize that it could influence plaque vulnerability by interfering in the cross-talk between macrophages (MØ) and smooth muscle cells (SMC). To examine its role and mechanism of action, we exposed an in-vitro co-culture system of SMC and MØ to ficolin-2 (10 µg/mL) and then performed cytokine array, protease array, ELISA, qPCR, Western Blot, and monocyte transmigration assay. Carotid plaque samples from atherosclerotic patients with high plasma levels of ficolin-2 were analyzed by immunofluorescence. We show that ficolin-2: (i) promotes a pro-inflammatory phenotype in SMC following interaction with MØ by elevating the gene expression of MCP-1, upregulating gene and protein expression of IL-6 and TLR4, and by activating ERK/MAPK and NF-KB signaling pathways; (ii) increased IL-1β, IL-6, and MIP-1β in MØ beyond the level induced by cellular interaction with SMC; (iii) elevated the secretion of IL-1β, IL-6, and CCL4 in the conditioned medium; (iv) enhanced monocyte transmigration and (v) in atherosclerotic plaques from patients with high plasma levels of ficolin-2, we observed co-localization of ficolin-2 with SMC marker αSMA and the cytokines IL-1β and IL-6. These findings shed light on previously unknown mechanisms underlying ficolin-2-dependent pathological inflammation in atherosclerotic plaques.

Identifiants

pubmed: 37940674
doi: 10.1038/s41598-023-46770-0
pii: 10.1038/s41598-023-46770-0
pmc: PMC10632380
doi:

Substances chimiques

Interleukin-6 0
Cytokines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

19431

Informations de copyright

© 2023. The Author(s).

Références

Chest. 2000 Aug;118(2):503-8
pubmed: 10936147
Circ Res. 2022 Jul 8;131(2):e22-e33
pubmed: 35713008
Front Mol Biosci. 2021 Mar 16;8:641734
pubmed: 33786327
Atherosclerosis. 2003 Oct;170(2):205-11
pubmed: 14612199
Biochim Biophys Acta. 2016 Jul;1863(7 Pt A):1568-78
pubmed: 27060293
J Clin Med. 2022 Mar 01;11(5):
pubmed: 35268451
Pharmacol Res. 2021 Apr;166:105462
pubmed: 33513354
J Cell Mol Med. 2012 Sep;16(9):1978-90
pubmed: 22348535
Cell Commun Signal. 2022 Nov 21;20(1):180
pubmed: 36411459
Atherosclerosis. 2012 Mar;221(1):2-11
pubmed: 21978918
Nat Rev Cardiol. 2022 Jan;19(1):43-58
pubmed: 34267377
Int J Mol Sci. 2016 Aug 24;17(9):
pubmed: 27563891
Sci Rep. 2017 Feb 20;7:43045
pubmed: 28216633
Vascul Pharmacol. 2015 Sep;72:108-17
pubmed: 25956731
Eur Heart J. 2018 Oct 7;39(38):3499-3507
pubmed: 30165610
Front Immunol. 2017 Mar 16;8:288
pubmed: 28360913
Commun Biol. 2022 Dec 1;5(1):1316
pubmed: 36456628
Br J Pharmacol. 2019 Oct;176(19):3741-3753
pubmed: 31254285
Int J Mol Sci. 2022 Oct 10;23(19):
pubmed: 36233314
Immunology. 2017 Aug;151(4):433-450
pubmed: 28380665
Am J Transl Res. 2022 Sep 15;14(9):6424-6444
pubmed: 36247305
J Intern Med. 2015 Nov;278(5):483-93
pubmed: 26260307
Cytokine. 2016 Jul;83:250-261
pubmed: 27180200
J Vasc Res. 2010;47(2):168-80
pubmed: 19851078
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Arterioscler Thromb Vasc Biol. 2022 Apr;42(4):372-380
pubmed: 35172605
Mol Med Rep. 2015 Aug;12(2):1665-76
pubmed: 25936371
Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):15-26
pubmed: 17082488
Congenit Heart Dis. 2016 May;11(3):213
pubmed: 27273932
J Immunol. 2016 Jun 15;196(12):5064-74
pubmed: 27183610
Atherosclerosis. 2015 Aug;241(2):480-94
pubmed: 26086357

Auteurs

Răzvan Daniel Macarie (RD)

Biopathology and Therapy of Inflammation Department, Institute of Cellular Biology and Pathology "Nicolae Simionescu", Bucharest, Romania.

Monica Mădălina Tucureanu (MM)

Biopathology and Therapy of Inflammation Department, Institute of Cellular Biology and Pathology "Nicolae Simionescu", Bucharest, Romania. monica.pirvulescu@icbp.ro.

Letiția Ciortan (L)

Biopathology and Therapy of Inflammation Department, Institute of Cellular Biology and Pathology "Nicolae Simionescu", Bucharest, Romania.

Ana-Maria Gan (AM)

Biopathology and Therapy of Inflammation Department, Institute of Cellular Biology and Pathology "Nicolae Simionescu", Bucharest, Romania.

Elena Butoi (E)

Biopathology and Therapy of Inflammation Department, Institute of Cellular Biology and Pathology "Nicolae Simionescu", Bucharest, Romania.

Ileana Mânduțeanu (I)

Biopathology and Therapy of Inflammation Department, Institute of Cellular Biology and Pathology "Nicolae Simionescu", Bucharest, Romania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH